Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Chiara Paoli, PhD, Paola Guglielmelli, MD PhD, Francesco Mannelli, MD, Lara Mannelli, MD, Vittorio Rosti, MD, Maria Chiara Finazzi, MD, Elisa Rumi, MD, Marco Ruggeri, Alessandro Pancrazzi, PhD, Carmela Mannarelli, PhD, Guido Finazzi, MD, Maria Luisa Ferrari, BSc, Laura Lissandrini, BSc, Duccio Fantoni, RN, Giovanni Barosi, Mario Cazzola, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1662.

https://doi.org/10.1182/blood-2019-122837

Published: 2019

Journal Articles

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 2968.

https://doi.org/10.1182/blood-2019-129094

Published: 2019

Journal Articles

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

Paola Guglielmelli, MD PhD, Giacomo Coltro, MD, Giuseppe Gaetano Loscocco, MD, Benedetta Sordi, MD, Francesco Mannelli, MD, Chiara Paoli, PhD, Ilaria Marone, PhD, Alessandro Pancrazzi, PhD, Francesca Gesullo, BSci, Carmela Mannarelli, PhD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2018-99-112287

Published: 2018

Journal Articles

Next-Generation Sequencing (NGS) in Childhood Myeloproliferative Diseases (MPD)

Michelina Santopietro, MD, Giovanna Palumbo, MD, Maria Luisa Moleti, MD, Anna Maria Testi, MD, Luisa Cardarelli, MD, Nicola Monaco, MDcal Student, Francesco Malaspina, MD, Camilla Presicce, MDcal Student, Sonia Maria Orlando, Alessandro Pancrazzi, PhD, Annalisa Pacilli, PhD, Giada Rotunno, PhD, Alessandro M. Vannucchi, MD, Robin Foà, MD, Fiorina Giona, MD

Blood (2018) 132 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2018-99-118102

Published: 2018

Journal Articles

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Alessandro M. Vannucchi, Annalisa Pacilli, PhD, Giada Rotunno, MSc, PhD, Francesco Mannelli, Chiara Paoli, BiSci, Carmela Mannarelli, MSc, PhD, Annalisa Franci, RN, Tiziana Fanelli, BiSc, Alessandro Pancrazzi, PhD, Francesca Gesullo, MSc, Giuditta Corbizi Fattori, BiSc, Alberto Bosi, MD, Paola Guglielmelli, MD PhD

Blood (2017) 130 (Supplement 1): 4195.

https://doi.org/10.1182/blood.V130.Suppl_1.4195.4195

Published: 2017

Journal Articles

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Blood (2017) 129 (24): 3227–3236.

https://doi.org/10.1182/blood-2017-01-761999

Published: 2017

Includes: Supplemental data

Journal Articles

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Paola Guglielmelli, PhDMD, Giada Rotunno, MSc, PhD, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Daniela Pietra, PhD, Silvia Salmoiraghi, BSc, Carmela Mannarelli, MSc, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 943.

https://doi.org/10.1182/blood.V128.22.943.943

Published: 2016

Journal Articles

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Alessandro Pancrazzi, BS, Tiziana Fanelli, MSc, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Marker Mahtab, Ana Rodriguez, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4087.

https://doi.org/10.1182/blood.V126.23.4087.4087

Published: 2015

Journal Articles

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Tiziana Fanelli, MSc, Carmela Mannarelli, MSc, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4091.

https://doi.org/10.1182/blood.V126.23.4091.4091

Published: 2015

Journal Articles

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Giada Rotunno, MSc, Tiziana Fanelli, MSc, Annalisa Pacilli, PhD, Laura Calabresi, BiSci, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1627.

https://doi.org/10.1182/blood.V126.23.1627.1627

Published: 2015

Journal Articles

JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment

Annalisa Pacilli, PhD, Paola Guglielmelli, MD PhD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Rajmonda Fjerza, MD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1630.

https://doi.org/10.1182/blood.V126.23.1630.1630

Published: 2015

Journal Articles

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Paola Guglielmelli, MD PhD, Giada Rotunno, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Daniela Pietra, PhD, Daniela Cilloni, MD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 351.

https://doi.org/10.1182/blood.V126.23.351.351

Published: 2015

Journal Articles

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Francesca Gesullo, BS, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Carmela Mannarelli, MSc, Giuseppe Loscocco, Chiara Paoli, BS, Lucia Merli, BSN, Alessandro M. Vannucchi

Blood (2015) 126 (23): 353.

https://doi.org/10.1182/blood.V126.23.353.353

Published: 2015

Journal Articles

JAK2 V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib

Lisa Pieri, Alessandro Pancrazzi, Annalisa Pacilli, Claudia Rabuzzi, Giada Rotunno, Tiziana Fanelli, Paola Guglielmelli, Rajmonda Fjerza, Chiara Paoli, Srdan Verstovsek, Alessandro M. Vannucchi

Blood (2015) 125 (21): 3352–3353.

https://doi.org/10.1182/blood-2015-01-624536

Published: 2015

Journal Articles

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

Lisa Pieri, MDPhD, Alessandro Pancrazzi, MSc, Annalisa Pacilli, PhD, Claudia Rabuzzi, BSci, Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Rajmonda Fjerza, MD, Chiara Paoli, MSc, Tiziana Fanelli, MSc, Alberto Bosi, MD, Srdan Verstovsek, MD PhD, Alessandro Maria Vannucchi, MD

Blood (2014) 124 (21): 3185.

https://doi.org/10.1182/blood.V124.21.3185.3185

Published: 2014

Journal Articles

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

Blood (2014) 124 (21): 3179.

https://doi.org/10.1182/blood.V124.21.3179.3179

Published: 2014

Journal Articles

Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

Blood (2014) 124 (21): 405.

https://doi.org/10.1182/blood.V124.21.405.405

Published: 2014

Journal Articles

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

Giada Rotunno, Carmela Mannarelli, Paola Guglielmelli, Annalisa Pacilli, Alessandro Pancrazzi, Lisa Pieri, Tiziana Fanelli, Alberto Bosi, Alessandro M. Vannucchi

Blood (2014) 123 (10): 1552–1555.

https://doi.org/10.1182/blood-2013-11-538983

Published: 2014

Includes: Supplemental data

Journal Articles

Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN

Elena Tenedini, PhD, Isabella Bernardis, MSc, Valentina Artusi, MSc, Lucia Artuso, PhD, Enrica Roncaglia, PhD, Paola Guglielmelli, PhD MD, Lisa Pieri, PhD MD, Costanza Bogani, PhD, Flavia Biamonte, BiSci, PhD, Elisa Bianchi, PhD, Alessandro Pancrazzi, BiSci, Carmela Mannarelli, BiSci, Tiziana Fanelli, BiSci, Giada Rotunno, BiSci, Guidantonio Malagoli Tagliazucchi, MSc, Sergio Ferrari, MD, Rossella Manfredini, PhD, Alessandro M Vannucchi, MD, Enrico Tagliafico, MD PhD

Blood (2013) 122 (21): 4099.

https://doi.org/10.1182/blood.V122.21.4099.4099

Published: 2013

Journal Articles

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Blood (2013) 122 (21): 104.

https://doi.org/10.1182/blood.V122.21.104.104

Published: 2013

NARROW

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

JAK2 V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis

Next-Generation Sequencing (NGS) in Childhood Myeloproliferative Diseases (MPD)

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

JAK2 V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2 V617F Mutation: A Study from the AGIMM Group

Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN

Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only